Cargando…
Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple-negative breast cancer cells
Although the anticancer drugs paclitaxel and doxorubicin are commonly used to treat many solid tumors, their effectiveness is highly variable due to tumor cell resistance. Therefore, it is important to find mechanisms that can be targeted to increase the sensitivity of cancer cells to current chemot...
Autores principales: | LEE, JAEHYUNG, GOLLAHON, LAUREN |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3597451/ https://www.ncbi.nlm.nih.gov/pubmed/23340795 http://dx.doi.org/10.3892/ijo.2013.1788 |
Ejemplares similares
-
Mitotic perturbations induced by Nek2 overexpression require interaction with TRF1 in breast cancer cells
por: Lee, Jaehyung, et al.
Publicado: (2013) -
Kinome-Wide siRNA Screening Identifies Src-Enhanced Resistance of Chemotherapeutic Drugs in Triple-Negative Breast Cancer Cells
por: Tzeng, Yen-Dun Tony, et al.
Publicado: (2018) -
Cytotoxicity of Selenium Immunoconjugates against Triple Negative Breast Cancer Cells
por: Khandelwal, Soni, et al.
Publicado: (2018) -
Nek2 siRNA therapy using a portal venous port–catheter system for liver metastasis in pancreatic cancer
por: Kokuryo, Toshio, et al.
Publicado: (2016) -
CSA Antisense Targeting Enhances Anticancer Drug Sensitivity in Breast Cancer Cells, including the Triple-Negative Subtype
por: Filippi, Silvia, et al.
Publicado: (2022)